04-Nov-2026 18:37:19
SMSPHARMAGeneral news
SMSPHARMA Q2 : CONS NET PROFIT UP 57% AT ₹40 CR (YOY), UP 96% (QOQ). STRONG (ON 1ST LOOK)
Revenue up 30% at ₹316.08 Cr (YOY), up 53% (QOQ); H1FY27 revenue up 19% at ₹523.05 Cr (YOY). Ebitda up 40% at ₹67.65 Cr (YOY), up 65% (QOQ); margins 21% v 20% (YOY), 20% (QOQ). Gross margin 35% v 32% (YOY), 36% (QOQ); PAT margin 13% v 10% (YOY), 10% (QOQ). FY27 revenue growth and EBITDA margins now expected to exceed earlier guidance. Impact: Strong YoY and QoQ profit growth with guidance upgrade.
SMS Pharmaceuticals Limited
Open attachment